Equities Research Analysts' Updated EPS Estimates for April 4th (ABUS, ACLX, AMD, AMPX, ANIC, ARM, ASXC, AZN, BAC, BALL)

Equities Research Analysts’ updated eps estimates for Thursday, April 4th: Arbutus Biopharma (NASDAQ:ABUS) had its market outperform rating reaffirmed by analysts at JMP Securities. JMP Securities currently has a $4.00 price target on the stock. Arcellx (NASDAQ:ACLX) had its outperform rating reaffirmed by analysts at Scotiabank. The firm currently has a $82.00 target price on […]

Related Keywords

United States ,Blackrock ,Nova Scotia ,Canada ,America ,Piper Sandler ,Raymond James ,Roth Mkm ,Radian Group ,Telsey Advisory Group ,Evolution Petroleum ,Mawson Infrastructure Group ,Elevance Health ,Citigroup Inc ,Knights Group ,Barclays Plc ,Canaccord Genuity Group Inc ,Needham Company ,Goldman Sachs Group Inc ,Intercontinental Exchange ,Nasdaq ,Morgan Stanley ,Cc Group ,Cantor Fitzgerald ,Unitedhealth Group ,Animal Health Group ,Montrose Environmental Group ,News Ratings For Arbutus Biopharma Co Daily ,Term Municipal Advantage Trust ,Scotiabank ,Royal Bank ,Arbutus Biopharma Co ,Equities Research Analyst ,Oppenheimer Holdings Inc ,Micron Technology ,Motorpoint Group ,Jefferies Financial Group Inc ,Jpmorgan Chase Co ,Micro Devices ,Rock Long Term Municipal Advantage Trust ,Goldman Sachs Group ,Global Markets ,Telsey Advisory ,Health Group ,Jefferies Financial Group ,Products Partners ,Cure Medical ,Environmental Group ,Infrastructure Group ,Owl Capital ,Gen Pharma ,Arbutus Biopharma Co Daily ,